Stabilitech Ltd (London) announced today that is has been awarded a grant by the Technology Strategy Board as part of its competition on Detection and Identification of Infectious Agents: Fighting Infection through Detection.
Stabilitech Ltd, the protein stabilisation company, announced today that it has signed a contract with the United States Defense Threat Reduction Agency (DTRA),
Stabilitech Ltd, a private company developing proprietary thermal stabilisation technologies for the vaccine and biopharmaceutical markets, is pleased to announce today that it has successfully raised £3.3 million of equity finance from new and existing investors, including business angels and high net worth individuals.
Stabilitech is very pleased to announce that Dr Peter Cozens has recently joined Stabilitech’s Board as non-executive director. Peter has worked for more than 30 years in the pharmaceutical industry, with broad international experience in both the biotechnology and conventional pharmaceutical sectors of the industry.
Stabilitech is Winner of the Environment Award in London Technology Fund Competition 2008 Stabilitech’s technology protects efficacy, reduces wastage and saves energy.
Dr Barbara Domayne-Hayman has joined Stabilitech as CEO. Barbara was previously Commercial Director at Arrow Therapeutics prior to their acquisition by AstraZeneca.
